Answers are grounded in this paper and cite their sources.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐related deaths globally. Current therapeutic options remain limited by poor efficacy, and there is an urgent need to identify new therapeutic targets and strategies. Metabolic reprogramming is a hallmark of HCC progression, and intercellular crosstalk within the tumor microenvironment (TME) critically shapes tumor cell metabolism. However, the cell types and mechanisms regulating HCC cell metabolism remain largely unclear. In this study, by combining single‐cell RNA sequencing (scRNA‐seq) and spatial transcriptomic data, we found that M2‐like tumor‐associated macrophages (TAMs) were associated with highly metabolic HCC cells. Using intercellular protein interaction detection (ICPID), a proximity‐labeling method developed in this study, we identified that Galectin‐9 (Gal‐9), highly expressed and secreted by M2 macrophages, is a ligand for the glutamine transporter SLC1A5 on HCC cells. This glycan‐dependent interaction promoted the membrane localization of SLC1A5, thereby enhancing glutamine uptake and metabolism to promote HCC growth. Gal‐9 neutralization or SLC1A5 inhibition suppressed glutamine metabolism and tumor‐promoting phenotypes both in vitro and in vivo. Our study shows that M2 macrophage‐derived Gal‐9 can promote HCC progression by directly enhancing glutamine metabolism in HCC cells, and that the Gal‐9‐SLC1A5 axis may serve as a new therapeutic target for HCC treatment.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: